Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...

Exxon spent the past year moving a lab's operations from California to Baytown and plans to increase its number of employees ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Biden’s decision underscored two key challenges with the current CFIUS process: the absence of a clear tiered framework to ...

We recently published a list of 10 Best Stocks To Buy For Financial Stability. In this article, we are going to take a look ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Alternative splicing (AS), a ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...